Skip to main content Skip to main content
Go to homepage

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Description:

For complete information, please view the study at clinicaltrials.gov

Study Status:
Closed
Study Sponsor:

Children's Oncology Group

Full IRB Study Title:
Phase II Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
IRB Study ID:
150914
If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org

Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.